PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 153 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 1.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $52,000 | -45.3% | 12,321 | -18.4% | 0.00% | -25.0% |
| Q3 2018 | $95,000 | -23.4% | 15,093 | -2.1% | 0.00% | -20.0% |
| Q2 2018 | $124,000 | +21.6% | 15,420 | +13.0% | 0.01% | +25.0% |
| Q1 2018 | $102,000 | +47.8% | 13,645 | +17.2% | 0.00% | +33.3% |
| Q4 2017 | $69,000 | -28.9% | 11,644 | -18.1% | 0.00% | -25.0% |
| Q2 2017 | $97,000 | -24.2% | 14,223 | +5.1% | 0.00% | -33.3% |
| Q1 2017 | $128,000 | – | 13,535 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 17,902,338 | $135,342,000 | 5.88% |
| TIGER MANAGEMENT L.L.C. | 1,288,454 | $9,741,000 | 1.91% |
| Phocas Financial Corp. | 1,047,181 | $7,917,000 | 0.69% |
| TUDOR INVESTMENT CORP ET AL | 2,370,503 | $17,921,000 | 0.62% |
| EAM Investors, LLC | 553,309 | $4,183,000 | 0.58% |
| Baker Brothers Advisors | 4,449,797 | $33,640,000 | 0.34% |
| TFS CAPITAL LLC | 463,740 | $3,506,000 | 0.33% |
| FEDERATED HERMES, INC. | 13,508,290 | $102,123,000 | 0.32% |
| Rotella Capital Management, Inc. | 36,473 | $276,000 | 0.24% |
| OXFORD ASSET MANAGEMENT LLP | 1,103,848 | $8,351,000 | 0.18% |